Login to Your Account



Medigene licenses Rhudex in PBC to Dr. Falk Pharma

By Cormac Sheridan
Staff Writer

Wednesday, March 19, 2014
Shares in Medigene AG edged up 8 percent Thursday on news of a licensing deal for its small-molecule CD80 (B7-1) inhibitor Rhudex with Dr. Falk Pharma GmbH. disclosed, but the deal is limited to hepatology and gastroenterology.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription